Last checked at 6 Jan 2021 15:58
Tissue Regenix Group plc
PDMR Dealings
Leeds, 6 January 2021 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group",) the regenerative medical devices company, has been notified that Trevor Phillips, independent Non-Executive Director of the Group, purchased 2,777,770 ordinary shares of 0.1p each in the Group ("Ordinary Shares") at a price of 0.54p per Ordinary Share for a total consideration of £14,999.96, on 6 January 2021.
Following this purchase, Mr. Phillips is beneficially interested in a total of 2,777,770 Ordinary Shares, representing approximately 0.04 per cent. of the Group's issued share capital.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For more Information:
Tissue Regenix Group plc Caitlin Pearson Head of Communications |
Tel: 0330 430 3052 |
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price | Tel: 0207 710 7600
|
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
1
| Details of the person discharging managerial responsibilities / person closely associated | |
a)
| Names | Trevor Phillips |
2
| Reason for the notification | |
a)
| Position/status
| Independent Non-Executive Director |
b)
| Initial notification /Amendment
| Initial notification |
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a)
| Name
| Tissue Regenix Group plc |
b)
| LEI | 213800PNOD5UHQUFJI36 |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a)
| Description of the financial instrument, type of instrument
| Ordinary Shares of 0.1p each |
b) | Identification code
| GB00B5SGVL29 |
c)
| Nature of the transaction
| Purchase of Ordinary Shares |
d)
| Price(s) and volume(s) | Volume(s): 2,777,770 Ordinary Shares Price: 0.54 pence per Ordinary Share |
d)
| Aggregated information - Aggregated volume - Price | N/A |
e)
| Date of the transactions | 6 January 2021 |
f)
| Place of the transaction | AIM |